Replies to post #831 on Idenix Pharmaceuticals (IDIX)

[DewDiligence]

>still think market has discounted NM283 to no value.<

This has been the case for some time, IMO. In order for this to change, NVS and IDIX will have to reveal what their “creative idea” is for resuscitating the NM283 program. Creativity is now needed in both the treatment-refractory and treatment-naïve settings.